Experienced in Leukemia

Zoltan T. Matrai

7-9. Ráth György Str, 
Budapest, BU, HU 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Leukemia
7-9. Ráth György Str, 
Budapest, BU, HU 
OverviewLocationsClinical Research

Overview

Zoltan Matrai practices in Budapest, Hungary. Mr. Matrai is rated as an Experienced expert by MediFind in the treatment of Leukemia. His top areas of expertise are Breast Cancer, Adult Soft Tissue Sarcoma, Desmoid Tumor, Fibromatosis, and Mastectomy.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 15 articles in the study of Leukemia.

Gender
Male

Locations

7-9. Ráth György Str, Budapest, BU 1122, Hungary
Other Locations
Ráth György Str. 7-9. 1122, Budapest, BU 1122, Hungary
Ráth György Str. 7-9, Budapest, BU 1122, Hungary
Head And Neck, Budapest, BU, Hungary

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS). A Multicenter Randomized Phase III Trial (OPBC-03/ SAKK 23/16 /IBCSG 57-18 / ABCSG-53 / GBG-101)
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS). A Multicenter Randomized Phase III Trial (OPBC-03/ SAKK 23/16 /IBCSG 57-18 / ABCSG-53 / GBG-101)
Enrollment Status: Recruiting
Publish Date: February 03, 2025
Intervention Type: Procedure, Radiation
Study Phase: Not Applicable

112 Total Publications

The Neutrophil-to-Lymphocyte Ratio May be the Best Serological Biomarker in Predicting Longer Survival in Neoadjuvant Treatment of Triple-Negative Breast Cancer.
The Neutrophil-to-Lymphocyte Ratio May be the Best Serological Biomarker in Predicting Longer Survival in Neoadjuvant Treatment of Triple-Negative Breast Cancer.
Journal: Cancer investigation
Published: December 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Matrai's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile